Notice of AGM

RNS Number : 6729J

Scancell Holdings Plc

20 August 2019

 

20 August 2019

Scancell Holdings Plc

("Scancell" or the "Company")

Notice of AGM

Scancell, the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting ("AGM") on Thursday 12 September 2019. The Notice of the AGM will be posted to shareholders today and a copy will be available on the Company's website.

The AGM details are as follows:

Date:	Thursday 12 September 2019
Time:	2.00pm
Venue:	The Kassam Stadium Grenoble Road Oxford OX4 4XP

For Further Information:

Scancell Holdings Plc
Dr John Chiplin, Chairman		[phone]
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		[phone]
FTI Consulting Simon Conway/Natalie Garland-Collins		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody^® and Moditope^® technology platforms.

ImmunoBody^® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·      SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·      SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope^® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope^® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

For further details, please see our website:  www.scancell.co.uk

 

END

 

 

NOABXGDIGDDBGCG